Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia
Phase II Study on the Efficacy, Safety, and Pharmacokinetics of HS-20106 in Patients With IPSS-R Very Low-risk, Low-risk, or Moderate-risk Myelodysplastic Syndrome (MDS) Anemia is a PHASE2 clinical asset sponsored by Hansoh BioMedical R&D Company in Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease. SEO and diligence focus: HS-20106, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Myelodysplastic Syndromes
Modality: small molecule
Target: HS-20106
Sponsor: Hansoh BioMedical R&D Company
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: HS-20106
View original source fields
Condition raw: Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease
Condition normalized: Myelodysplastic Syndromes, Anemia, MDS, Bone Marrow Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: HS-20106
Target normalized: HS-20106